several human postnatal somatic cell types have been successfully reprogrammed to induced pluripotent stem cells (ipscs). Blood mononuclear cells (Mncs) offer several advantages compared with other cell types. they are easily isolated from umbilical cord blood (cB) or adult peripheral blood (pB), and can be used fresh or after freezing. a short culture allows for more efficient reprogramming, with ipsc colonies forming from blood Mncs in 14 d, compared with 28 d for age-matched fibroblastic cells. the advantages of briefly cultured blood Mncs may be due to favorable epigenetic profiles and gene expression patterns. Blood cells from adults, especially nonlymphoid cells that are replenished frequently from intermittently activated blood stem cells, are short-lived in vivo and may contain less somatic mutations than skin fibroblasts, which are more exposed to environmental mutagens over time. We describe here a detailed, validated protocol for effective generation of integration-free human ipscs from blood Mncs by plasmid vectors.
IntroDuctIon
Human iPSCs have been derived from many cell types, includ ing blood cells, since 2007 (refs. 1-7). The original protocol using retroviral vectors expressing Oct4 (officially known as Pou5f1), Sox2, Klf4 and c-Myc (officially known as Myc) has proven to be successful in most of the reported reprogramming experiments. To make iPSCs safer for regenerative medicine and more reli able for disease modeling, efforts have been made to derive iPSCs without the integration of exogenous DNA into cellular genomes. Conceptually, the most straightforward strategies include deli very of reprogramming factors to the cells in the form of recom binant proteins or mRNAs. The feasibility of these strategies has been shown by proofofprinciple experiments 8, 9 . However, the reprogramming efficiencies using proteins have been low, and this method requires repetitive delivery of multiple proteins and mRNAs into the fibroblast cells on a daily basis for up to 17 d, thus markedly limiting the application of these technologies in most laboratories. Although future improvement of these genetically safer technologies is required for widespread use, plasmid vectors containing the EBNA1/OriP sequences of the EpsteinBarr virus replicon have provided an effective alternative for reprogramming human somatic cells. Human iPSC lines were established by one time transfection of neonatal foreskin fibroblasts by 2-3 plasmids encoding seven different reprogramming factors or fetal neural progenitor cells with fewer factors 10, 11 . These studies demonstrated the feasibility of using EBNA1/OriPcontaining plasmids to achieve prolonged plasmid retention and gene expression in transfected somatic cells, allowing iPSC induction of human somatic cells that require longer times (in weeks) of transgene expression. However, the efficiency using the reported episomal vectors for reprogram ming postnatal human somatic cells is too low to be a routine method for most investigators.
Development of the protocol
To develop a protocol that generates integrationfree iPSCs more efficiently from easily accessible cell sources, we studied the epigenetic features of various cell types, as well as reprogramming efficiencies 7, 12, 13 . We discovered that blood MNCs, either purified CD34 + hematopoietic stem/progenitor cells (HSPCs) or unfrac tionated cells after a brief culture, possess unique epigenetic sig natures that are closer than those of the agematched fibroblasts to embryonic stem cells (ESCs) and iPSCs 7, 13 . A MNC expansion protocol, which preferentially enriches for erythroblastlike cells and eliminates lymphocytes, alleviates the need for isolation of CD34 + HSPCs before reprogramming. By using MNCs with favo rable epigenetic profiles, we have also tested an improved EBNA1/ OriPbased plasmid system that expresses five reprogramming factors (Oct4, Sox2, Klf4, cMyc and Lin28) as a single unit linked by 2A cleavable peptide sequences. We have found that a single transfection of this single plasmid into expanded/primed umbilical CB MNCs can generate hundreds of TRA160-positive iPSC colo nies in 2 weeks 13 . Although the reprogramming efficiency with the single vector is much lower in adult blood MNCs, addition of another factor (e.g., SV40 large T antigen) by cotransfection of second episomal vector enhances the reprogramming efficiency by four to fivefold 13 . Overall, this episomal vector system and the cell expansion/priming protocol make it possible to derive iPSC clones from as little as a few milliliters of postnatal blood (Fig. 1) .
We have carried out wholegenome sequencing on human iPSC lines derived using this episomal vector system 14 . Through rig orous sequencing analyses, we have not only further confirmed that there is no plasmid integration, but also demonstrated a low incidence of DNA sequence variation in these iPSCs com pared with their somatic cell origin. Our data indicate that this episomemediated reprogramming is not inherently muta genic during integrationfree iPSC induction. More recently, we replaced mouse feeder cells with engineered human feeder cells 15 . Thus, this plasmidbased protocol for derivation of integrationfree human iPSCs by using blood cells and under defined culture conditions provides a powerful and safe tool for both stem cell research and future regenerative medicine.
Comparison with other methods
Several other methods have been reported using viral vectors for repro gramming of human blood cells with out isolation of HSPCs [16] [17] [18] [19] [20] [21] . The most attractive method is the use of recombinant Sendai (nonintegrating RNA) viruses to reprogram activated human T lymphocytes that can be effi ciently infected 21 . Compared with these methods that preferentially expand and/or infect activated T lymphocytes within MNCs for reprogramming using viral vectors, the protocol described here uses plasmid DNA to generate human iPSCs that contain the intact germline genomes: they are not only free of trans gene integration, but also lack V(D)J somatic rearrangements that are present in T lymphocytes. Thus, the iPSCs generated from non lymphocytes that have intact nuclear genomes may be more suitable for therapy purposes. The absence of prerearranged V(D)J DNA segments in the iPSC genome may also eliminate certain safety concerns raised by the observation that mice derived from repro grammed T cells have a high rate of T cell lymphomas 22 . Recently, another episomal plasmidbased protocol has also been reported to generate integrationfree iPSCs from human bone marrow and CB cells without enriching for HSPCs or T lymphocytes 23 . The method differs from the protocol described here in the combina tions of reprogramming factors and in the cell preparation condi tions. The reprogramming efficiency of adult PB MNCs using the protocol described in this report is currently unclear 23 . Although the two methods of using episomal vectors are overall similar in derivation of integrationfree iPSC lines from hematopoietic cells, they differ in the numbers of episomal vectors used and the culture conditions to prime hematopoietic cells for reprogramming. To reduce the possibility that derived IPSC lines would be from T and B lymphocytes that are present at high levels (> 50%) in CB and adult PB than in bone marrow, we cultured unfractionated MNCs for 8-14 d to enrich and expand erythroblasts (and eliminate lymphocytes) before reprogramming. Flow cytometric analysis after blood MNC expansion showed that the percentage of T or B lymphocytes present in the culture decreases to < 4%, whereas the erythroblasts increased from ~1% to a range of 11-52% (ref. 13 ).
Limitations of the protocol
Derivation of integrationfree human iPSCs from small amounts of unfractionated human blood offers key advantages in modeling a broad range of human diseases, including those that may carry blood cell-specific somatic mutations. The intact genomes (with out inserted foreign DNA sequences or V(D)J somatic recombina tion) of the iPSCs may be more suitable for regenerative medicine purposes. However, this protocol uses an expansion condition that preferentially expands erythroblasts, and therefore may not be suitable for reprogramming blood cells from patients who have a deficiency in erythroblast formation. In these cases, we recom mend considering an alternative protocol 23 .
The protocol described here provides robust reprogramming of CB MNCs without a need to isolate a subpopulation. The efficiency of reprogramming adult PB MNCs is substantially (20-50×) lower than that of CB MNCs. This is a major drawback, especially when compared with the method using viral vectors with CD34 + or activated T cells 21 . We and others have found that adding sodium butyrate during reprogramming can enhance the efficiency of human iPSC derivation 12, 13, 24, 25 , allowing sufficient numbers of iPSC colonies (≥12) to be formed after 12 d in a single experiment using 2 × 10 6 expanded erythroblasts initiated from 2 × 10 6 or fewer blood MNCs. In practice, we normally pick up to 12 candidate iPSC clones from a given donor or patient and select the two or three best clones for characterization after expansion. In case the iPSC derivation efficiency from a given patient is not high enough, one may duplicate or triplicate sample sizes by using more starting blood MNCs (abundantly available) or enhance reprogramming by other means. For example, recent work described an array of small molecules reported to enhance reprogramming efficiency. These include, but are not limited to, the inhibitors targeting the ROCK, GSK3, TGFβ and MEK pathways 26, 27 . Certain microRNAs (miRNAs) have also been reported to enhance the reprogramming efficiency of human fibroblast cells 28, 29 , although their stimulatory effects have not yet been reported using nonintegrating vectors and blood cells. It is expected that certain combinations of these small molecules or miRNAs will also further boost the efficiency of the protocol described here.
Experimental design
Isolation of CB and PB MNCs. The first part of our protocol involves isolating MNCs from adult PB and umbilical CB samples. This is accomplished through the use of FicollPaque Premium (P = 1.077) for densitybased centrifugal separation. After a 30min spin, MNCs stay just above the Ficoll layer, whereas red blood cells ( > 99%) traverse through and sediment at the bottom. A small amount of red blood cells left in the MNC fraction can be removed after MNC collection by treatment with red cell lysis buffer, if necessary. supplemented with a mixture of cytokines. This culture condition favors the expansion of erythroblasts and will not support lym phocyte growth. The number of viable cells will decrease over the first few days of the expansion process, but will slowly grow from day 4 onward. This expansion stage not only drives the cells into the cell cycle, but also further primes the cells to certain epigenetic states that are more easily reprogrammed 13 . Since the publication of the original paper 13 , we have found that adding more holo transferrin (up to 100 µg ml − 1 ) to that present in the standard insulintransferrinseleniumX (ITSX) solution enhances consist ent erythroblast expansion. In general, CB MNCs have superior expansion capability under this condition. The reprogramming efficiency of CB MNCs is also much higher compared with that of adult PB MNCs. Therefore, we recommend using CB MNC samples for practice or as positive controls for both steps when PB MNCs are reprogrammed by this protocol.
Reprogramming of blood MNCs by episomal vector expression after transfection. The reprogramming process is initiated by a single transfection of an episomal plasmid, pEBC5, expressing five factors (Oct4, Sox2, Klf4, cMyc and Lin28; Fig. 2 ). This sin gle plasmid has been shown to efficiently reprogram CB MNCs 13 .
To further enhance the reprogramming efficiency of other types of cells, this vector can be supplemented with episomal plasmids expressing SV40 large T antigen (pEBTg) or shRNA against p53 (pEBp53shRNA) 13 . Although sustained T antigen expression and p53 knockdown using integrating vectors resulted in altered genomes in derived iPSCs, transient expression of T antigen by episomal vectors during reprogramming did not have a detri mental effect on iPSC genomic integrity 13, 14, 30 . These episo mal plasmids are available from Addgene (plasmid nos. 28213
[pEBC5], 28220 [pEBTg] and 28222 [pEBp53shRNA]). After a single tranfection, the cells are plated back in the expansion medium to allow recovery. Two days later, they are plated onto standard plates coated with feeder cells, with the culture medium changed to ESC medium the following day. The reprogramming procedure is similar to those that have been used for fibroblast cell reprogramming and described in detail 24 . In most cases, iPSClike colonies that acquire TRA160 expression on the cell surface can be observed within 2 weeks after transfection of blood MNCs.
TRA-1-60 live staining for identifying successfully reprogrammed colonies. Along with assessing morphological differences, staining with TRA160-specific antibody can be used to distinguish suc cessfully reprogrammed colonies from other transformed noniPSC colonies. It has been shown that the combination of morphology and TRA160 live staining can reliably identify bona fide iPSC colonies 12, 13, 24, 31 . After staining, individual clones can be picked and expanded for further characterization. 
REAGENT SETUP Red cell lysis buffer Add 4.145 g of ammonium chloride, 0.5 g of potassium bicarbonate and 100 µl of EDTA to 400 ml of ultrapure water. Adjust the pH to the range of 7.2-7.4, and add ultrapure water to bring the volume to 500 ml. Filtersterilize the buffer and store it at 4 °C. Use the buffer within 6 months. SFM To prepare 500 ml of SFM, combine 245 ml of IMDM and 245 ml of Ham's F12 with 5 ml of ITSX, 5 ml of chemically defined lipid concentrate, 5 ml of lglutamine, 0.025 g of lascorbic acid, 2.5 g of BSA and 9 µl of 1thioglycerol (final concentration of 200 µM). Filtersterilize the medium and store it at 4 °C. Use the medium within 3 weeks. MNC medium MNC medium contains SFM supplemented with 100 ng ml − 1 SCF, 10 ng ml − 1 IL3 (10 ng ml − 1 ), 2 U ml − 1 EPO, 40 ng ml − 1 IGF1, 1 µM dexamethasone and 100 µg ml − 1 holotransferrin. Prepare the medium daily immediately before use. MEF medium To prepare 500 ml of MEF medium, combine 450 ml of DMEM with 50 ml of FBS, 5 ml of antibioticantimycotic and 5 ml of lglutamine. Filtersterilize the medium and store it at 4 °C. Use the medium within 3 weeks. ESC medium To prepare 600 ml of medium, combine 470 ml of knockout DMEM with 120 ml of KSR, 6 ml of antibioticantimycotic, 6 ml of lglutamine, 6 ml of MEMNEAA, 0.6 ml of 2mercaptoethanol and 10 ng ml − 1 bFGF. Filtersterilize the medium and store it at 4 °C. Use the medium within 3 weeks. Gelatin (0.1% wt/vol)-coated plates Apply 0. proceDure Donor cB and pB collection • tIMInG ~10 min 1| Collect 5-80 ml of donor PB by venipuncture into an appropriate vessel containing sodium heparin preservative, or collect whole CB from a donor (typically 100-200 ml) into an appropriate vessel containing citrate phosphate dextrose preservative. ! cautIon Informed consent from patients must be obtained before collection.  pause poInt CB and PB should be stored and shipped at 25 °C. Do not use samples that are older than 24 h. It is much better to freeze isolated MNCs than whole blood for later use.
Isolation of cB and pB Mncs via density gradient • tIMInG ~2.5 h 2| Dilute the CB or PB 1:2 with sterile PBS in an upright, appropriately sized sterile tissue culture flask or tube. Use a T150 flask for large volumes and a 50-ml conical tube for small volumes.  crItIcal step This and all subsequent steps should be carried out in a class II biological safety cabinet.
3|
Carefully and slowly layer 35 ml of diluted blood onto 15 ml of Ficoll-Paque Premium in a 50-ml conical tube. Repeat the process in additional conical tubes containing Ficoll-Paque Premium for the remaining diluted blood. If the last amount does not total 35 ml, add PBS.  crItIcal step Take care to minimize mixing of the layers by tilting the tube at a 45° angle and allowing the blood to run down the side of the tube onto the Ficoll layer. This will ensure a tight band of MNCs after isolation.
 crItIcal step Red blood cells will settle to the bottom of the tube as the diluted blood is added. This is normal, as the red blood cells are denser than the Ficoll.
4|
Centrifuge the tubes at 750g for 30 min at 25 °C in a swinging bucket rotor.  crItIcal step This step must be performed with the centrifuge brake off. This will allow for proper separation.
5|
Aspirate the upper, yellow layer containing plasma from each tube and discard it. Carefully transfer each cloudy white interphase layer containing MNCs to a new 50-ml conical tube with a 10-ml pipette.
6| Add 30 ml of PBS to each tube containing the MNCs and centrifuge the tubes at 350g for 10 min at 4 °C. This step and subsequent steps should be performed with the centrifuge brake on.
7|
Discard the supernatant, and combine and resuspend the pellets in one 50-ml conical tube with 5 ml of red cell lysis buffer. Let the cells incubate at 25 °C for 10 min. Fill the tube with PBS to dilute the lysis buffer.
8|
Centrifuge the cells at 300g for 10 min at 4 °C.
9|
Discard the supernatant and resuspend the pellet in 25 ml of PBS.
10|
11|
Repeat Steps 9 and 10 once.
12|
Discard the supernatant and resuspend the pellet in 5 ml of PBS. 
18| Count the number of viable cells (in an aliquot).
 crItIcal step At day -5 (CB) or day -11 (PB), the cell number should have decreased. This is expected.
19|
Plate the cells in a six-well plate at a density of 0.5-1 million per milliliter of MNC medium and incubate them for 3 d. 
23|
Count cultured CB or PB MNCs, and then transfer 2 million cells to a 15-ml conical tube containing 5 ml of PBS.
24|
Centrifuge the cells at 200g for 5 min at 25 °C. Discard the supernatant completely and carefully resuspend the pellet in 100 µl of human CD34 + cell nucleofector solution.
25|
Combine the 100-µl cell suspension with 10 µg of plasmid DNA (≥1 µg µl − 1 ) of the pEB-C5 episomal vector. If you plan to use the pEB-C5 + pEB-Tg vector combination for transfection, the ratio is 8 µg of pEB-C5 to 2 µg of pEB-Tg.
26|
Immediately transfer the cell/DNA mixture to a sterile cuvette (provided with the Lonza kit).
27|
Place the cuvette into the cuvette holder of the Amaxa Nucleofector II device and apply program 'T-016' .
28|
When the program is complete, remove the cuvette. Carefully transfer the solution from the cuvette using a plastic pipette (provided with the Lonza kit) into 2 ml of MNC medium and plate it in one well of a 12-well plate. Incubate for 2 d at 37 °C, 5% CO 2 .
? trouBlesHootInG 29| Day 2 after transfection. Collect transfected cells with a sterile 5-ml pipette and place into a 15-ml conical tube. Centrifuge the cells at 200g for 5 min at 25 °C. Remove and discard the supernatant and resuspend the pelleted cells in 1 ml of MEF medium.
30|
Count the cells and transfer them in MEF medium to a MEF-coated 12-well plate at a density of ~100,000 cells per well.
31|
Spin the sealed plates at 200g for 30 min at 25 °C. When the spin is finished, incubate the plates at 37 °C, 5% CO 2 overnight.
32| Day 3 after transfection.
Remove the medium from the culture and transfer to 15-ml conical tubes. Add 0.5 ml of ESC medium to each well. Centrifuge the tubes at 300g for 5 min at 25 °C and aspirate the top medium without removing cell pellets at the bottom of the tubes. Resuspend the pellet with 0.5 ml of ESC medium and plate back to the MEF plate so that there is 1 ml of ESC medium per well. Incubate the cells for 48 h. If desired, NaB (0.25 mM) can be added to the cultures to enhance iPSC derivation. Continue supplementation until colonies are ready to be picked (on days 10-14 after transfection; see Step 36).
33| Day 5 after transfection.
Aspirate the medium from the cultures, discard it and replace it with ESC medium at a volume of 1 ml per well. Incubate the cells for a further 48 h.
34| Day 7 after transfection.
35| Day 9 after transfection.
Aspirate the medium from the cultures, discard it and replace it with CM at a volume of 1 ml per well. Incubate the cells for 24 h.  crItIcal step The use of CM is necessary at this time to maintain colony growth.
36|
Days 10-14 after transfection. Check the cells daily, continuing to incubate and change the medium every other day. During days 10-14, large colonies should be visible and should be characterized as described in the next section before further passage.
? trouBlesHootInG tra-1-60 staining to identify fully reprogrammed colonies • tIMInG 1-2 d 37| On the day before staining, prepare a 96-well MEF-coated plate as described in Reagent Setup. MEFs should be plated at a density of ~12,500 cells per well.
38|
On the day of staining, dilute TRA-1-60 antibody to 1:300 and Alexa Fluor 555-conjugated secondary antibody to 1:500 in ESC medium.
39|
Aspirate the medium from the colony-containing wells, discard and add 0.5 ml of the antibody-containing ESC medium to each well. Incubate the cells at 37 °C, 5% CO 2 for 1 h.
40|
Aspirate off the medium, discard it and wash each well with 1 ml of PBS.
41| Add 1 ml of ESC medium per well and examine the colonies with an inverted microscope properly equipped for fluorescence.
42|
Cut TRA-1-60-positive colonies with sterile, pulled glass Pasteur pipettes. Remove each colony with a micropipette and place it into one well of a 96-well MEF-coated plate containing ESC medium. Repeat this process to obtain a sufficient number of clones for expansion.
43|
Incubate the cells, aspirating and replacing the medium daily. Colonies should expand and be ready to passage in 4-5 d.
Cultures can be passaged according to standard iPSC protocols 2,24 .
? trouBlesHootInG Troubleshooting advice can be found in table 1.
• tIMInG
Step 1, donor CB and PB collection: ~10 min Steps 2-14, isolation of CB and PB MNCs using Ficoll-Paque Premium density gradient: ~2. In our experience, the selection of blood collection tubes and the storage conditions of the blood after drawing can markedly affect the viability of blood MNCs and the subsequent expansion. In our hands, CB preserved in citrate phosphate dextrose and PB preserved in sodium heparin and sodium citrate have been successfully expanded. Blood should be transported at 25 °C and the procedure should be started within 24 h for best results. For expansion of PB cells, it may take up to 11 d to achieve sufficient cell numbers for reprogramming. In addition, the quality of the components of the SFM should be considered
28
Excessive cell death or low transfection efficiency
It is important to have high-quality plasmid DNA. The concentration of plasmid is also important; we recommend having at least 1 µg µl − 1 to minimize the volume added to the nucleofection solution 36 Poor colony growth It is important to have high-quality feeder cells (MEFs) that are appropriate for the expansion of iPSCs. If the MEF morphology begins to look poor during cell culture for reprogramming, supplementing hESC medium with CM will help sustain the growth of iPSCs
